<DOC>
	<DOCNO>NCT00406471</DOCNO>
	<brief_summary>The RAVE ( Rubeosis Anit-VEgf ) trial , utilizes monthly intravitreal Ranibizumab ( Lucentis ) injections 9 month see total VEGF blockade prevent neovascular glaucoma eliminate need panretinal photocoagulation patient ischemic central retinal vein occlusion .</brief_summary>
	<brief_title>Rubeosis Anti-VEGF ( RAVE ) Trial Ischemic Central Retinal Vein Occlusion</brief_title>
	<detailed_description>The devastate complication ischemic CRVO development anterior segment neovascularization result morbidity neovascular glaucoma . This complication appear directly correlate intraocular VEGF level . Currently proven treatment decrease formation rubeosis . Current management disease consist pan-retinal photocoagulation significant anterior segment neovascularization become manifest . This treatment destroy peripheral retina ( peripheral retinal field ) presumably work eventually lowering ocular VEGF level cause secondary regression rubeosis . As ranibizumab block VEGF , treatment deliver intraocularly may prevent neo-vascular glaucoma preserve peripheral visual field patient population . Risks intravitreal injection well know include endophthalmitis retinal detachment . This risk less 1 % proper injection technique experience retinal surgeon . As incidence neovascular glaucoma ( resultant loss central peripheral visual field ) approximately 50 % ischemic CRVO , small risk intravitreal injection warrant drug show efficacy . In small number subject previous animal human trial , intraocular pressure acutely elevated drug volume place intravitreally . An eye compromise circulation ( ischemic CRVO ) may experience less perfusion occur . Previous intravitreal study ranibizumab utilized anterior chamber paracentesis compensate volume intravitreal drug place . This reasonable eye normal retinal circulation tolerate relatively high intraocular pressure limited time . This protocol study include anterior chamber paracentesis prior intravitreal injection minimize potential risk .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Ischemic CRVO within 3 month enrollment per follow inclusion criterion Three follow clinical test must present demonstrate ischemic CRVO : VA 20/200 bad RAPD 0.9 LU bad Loss 12e isopter Goldmann Visual field ( Kwon et al . 2001 ) ERG demonstrate b wave amplitude le 60 % A wave Angle neovascularization great 3 clock hour IOP 30 ( Neovascular glaucoma ) Any previous retinal laser photocoagulation study eye Any previous intravitreal injection study eye ( triamcinolone ) Any previous vitrectomy study eye ( posterior anterior associate vitreous loss cataract surgery ) Intracapsular cataract extraction ( posterior capsule need present ) Previous history retinal detachment study eye Any previous radiation treatment head/ neck Inability ass iris neovascularization ( corneal opacity preclude gonioscopy ) Significant cardiovascular disease cancer would prevent followup visit completion 12 month study Significant diabetic retinopathy fellow eye ( diabetic macular edema , proliferative diabetic retinopathy , highrisk nonproliferative diabetic retinopathy ) Pregnancy ( positive pregnancy test ) Prior enrollment study vein occlusion study eye Participation another simultaneous medical investigator trial Ocular disorder study eye may confound interpretation study result , include retinal detachment , macular hole , choroidal neovascularization cause ( e.g. , DME AMD , ocular histoplasmosis , pathologic myopia ) Concurrent disease study eye could compromise visual acuity require medical surgical intervention study period Aphakia absence posterior capsule study eye Previous violation posterior capsule also exclude unless occur result YAG laser posterior capsulotomy association prior , posterior chamber intraocular lens implantation History idiopathic autoimmune uveitis either eye Structural damage center macula study eye preexist CRVO likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) Vitreomacular traction epiretinal membrane study eye evident biomicroscopically OCT Ocular inflammation ( include trace ) study eye Uncontrolled glaucoma ( defined intraocular pressure ≥30 mm Hg despite treatment anti medication ) previous filtration surgery study eye Infectious blepharitis , keratitis , scleritis , conjunctivitis ( either eye ) current treatment serious systemic infection Spherical equivalent refractive error study eye 8 diopter myopia ( For patient refractive cataract surgery study eye , preoperative spherical equivalent refractive error 8 diopter myopia allow ) Systemic Conditions Uncontrolled Blood pressure exceed diastolic pressure 100 mm Hg ( sit ) screen period Uncontrolled diabetes mellitus Renal failure require dialysis renal transplant Premenopausal woman use adequate contraception Previous participation study investigational drug ( exclude vitamin mineral ) within 3 month precede Day 0 History disease , metabolic dysfunction , physical examination finding , finding give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication INR ≥ 3.0 ( e.g . due current treatment warfarin ) . The use aspirin exclusion . Other History allergy fluorescein , amenable treatment Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze graded central reading center Inability comply study follow procedure History allergy humanize antibody component ranibizumab formulation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Ischemic</keyword>
	<keyword>Central</keyword>
	<keyword>Retinal</keyword>
	<keyword>Vein</keyword>
	<keyword>Occlusion</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>CRVO</keyword>
	<keyword>ISCRVO</keyword>
</DOC>